Drug General Information (ID: DDIO9E3NAK)
Drug Name			Interferon alfa-2a, Recombinant		Drug Info		Zidovudine		Drug Info
Drug Type		Interferons				Small molecule
Therapeutic Class		Interferons				Anti-Hiv Agents

Mechanism of Interferon alfa-2a, Recombinant-Zidovudine Interaction (Severity Level: Major)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Interferon alfa-2a, Recombinant				Zidovudine
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Interferon alfa-2a, Recombinant and Zidovudine

Recommended Action
Management		Caution is advised if concomitant therapy is necessary, particularly with the alfa interferons. Complete blood counts, differential and platelet counts should be performed regularly and drug dosages adjusted accordingly. Patients should be advised to promptly report symptoms such as chills, fever, sore throat, pale skin, or unusual fatigue to their physician. Cessation of one or all drugs may be necessary if toxicity develops.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Intron A (interferon alfa-2b). Schering Laboratories, Kenilworth, NJ.
3	Nokta M, Loh JP, Douidar SM, Ahmed AE, Pollard RB "Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients." J Interferon Res 11 (1991): 159-64.[PMID: 1919075]